Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Total Non-Current Liabilities (2019 - 2025)

China SXT Pharmaceuticals has reported Total Non-Current Liabilities over the past 6 years, most recently at $158263.0 for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 46.89% year-over-year to $158263.0; the TTM value through Sep 2025 reached $158263.0, down 46.89%, while the annual FY2025 figure was $211683.0, 28.16% down from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $158263.0 at China SXT Pharmaceuticals, down from $211683.0 in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $365823.0 in Q1 2023 and troughed at $6292.0 in Q1 2021.
  • A 4-year average of $235178.7 and a median of $294667.0 in 2024 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: plummeted 82.77% in 2021 and later decreased 4.33% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $6292.0 in 2021, then soared by 4850.92% to $311512.0 in 2023, then dropped by 4.33% to $298011.0 in 2024, then tumbled by 46.89% to $158263.0 in 2025.
  • Business Quant data shows Total Non-Current Liabilities for SXTC at $158263.0 in Q3 2025, $211683.0 in Q1 2025, and $298011.0 in Q3 2024.